The study was published in JACC: Cardiovascular Interventions and simultaneously presented at TCT 2025 in San Francisco.

CARDIO inCode-Score Genetic Risk Influences Cholesterol Risk and Prediction of Coronary Heart Disease IRVINE, CA / ACCESS Newswire / October 28, 2025 / GENinCode, the predictive genetics company ...

New research reveals stem cell therapy significantly lowers heart failure risk in heart attack survivors. Patients receiving ...

Compared with the standard of care, an AI-based ECG model greatly reduced false positives for ST-elevation myocardial ...

Of note, the iMODERN trial had also excluded people with a history of prior STEMI, chronic total occlusion, complex ...

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also ...

Patients with weak heart function who receive stem cell therapy shortly after a heart attack are at lower risk of developing heart failure and related hospital stays compared with standard care, finds ...

The approval was based on the SOUL trial, which evaluated oral semaglutide in adults 50 years and older with T2DM and established CV disease and/or chronic kidney disease.

The approved ANDA is therapeutically equivalent to the reference listed drug Brilinta Tablets, 60 mg, of AstraZeneca Pharmaceuticals LP. Ticagrelor is indicated to reduce the risk of cardiovascular ...

Using artificial intelligence (AI) to analyze electrocardiograms (ECG) improved detection of severe heart attacks, including ...

Philips (NYSE: PHG) today announced results from the iMODERN trial evaluating immediate versus delayed treatment of narrowed ...

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.